Profile data is unavailable for this security.
About the company
Kineta, Inc. is a clinical-stage biotechnology company. The Company has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a monoclonal antibody (mAb), immunotherapy targeting VISTA (V-domain Ig suppressor of T cell activation), and an anti-CD27 agonist mAb immunotherapy. KVA12123 may be an effective immunotherapy for many types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian cancer (OC), renal cell carcinoma (RCC) and head and neck squamous cell carcinoma. It is also developing an anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The nominated lead candidate is a fully human mAb that demonstrates nanomolar (nM) binding affinity to CD27 in humans.
- Revenue in USD (TTM)0.00
- Net income in USD-20.88m
- Incorporated2006
- Employees11.00
- LocationKineta Inc7683 Se 27Th Street, Suite 481MERCER ISLAND 98040United StatesUSA
- Phone+1 (206) 378-0400
- Fax+1 (302) 636-5454
- Websitehttps://kinetabio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
TFF Pharmaceuticals Inc | 1.20m | -19.39m | 6.97m | 19.00 | -- | 1.11 | -- | 5.79 | -7.95 | -7.95 | 0.4659 | 1.81 | 0.1043 | -- | 3.51 | 63,293.68 | -168.10 | -79.57 | -212.66 | -83.41 | -- | -- | -1,612.04 | -8,687.66 | -- | -- | 0.00 | -- | 48.01 | -- | 33.13 | -- | -- | -- |
Alzamend Neuro Inc | 0.00 | -7.39m | 6.98m | 4.00 | -- | -- | -- | -- | -10.69 | -10.69 | 0.00 | -1.41 | 0.00 | -- | -- | 0.00 | -344.10 | -177.86 | -- | -257.81 | -- | -- | -- | -- | -- | -363.62 | -- | -- | -- | -- | 33.14 | -- | -- | -- |
Carmell Corp | 12.32k | -15.97m | 7.05m | 9.00 | -- | -- | -- | 571.84 | -1.53 | -1.44 | 0.0006 | -0.0656 | -- | -- | -- | 1,368.89 | -- | -- | -- | -- | 58.73 | -- | -129,263.60 | -- | 0.6901 | -- | -- | -- | -- | -- | -75.70 | -- | -- | -- |
ABVC Biopharma Inc | 136.40k | -11.37m | 7.09m | 16.00 | -- | 0.8298 | -- | 52.00 | -1.78 | -1.78 | 0.0172 | 0.6882 | 0.0114 | -- | 0.4213 | 8,525.00 | -99.79 | -103.38 | -197.79 | -231.54 | -24.11 | 76.25 | -8,762.13 | -2,019.89 | -- | -2.50 | 0.1873 | -- | -84.28 | 85.39 | 35.97 | -- | -- | -- |
Mosaic Immunoengineering Inc | 0.00 | -1.21m | 7.10m | 3.00 | -- | -- | -- | -- | -0.1674 | -0.1674 | 0.00 | -0.8904 | 0.00 | -- | -- | 0.00 | -634.64 | -- | -- | -- | -- | -- | -- | -- | -- | -14.05 | -- | -- | -- | -- | 57.65 | -- | -- | -- |
Moleculin Biotech Inc | 0.00 | -25.17m | 7.11m | 18.00 | -- | 0.3616 | -- | -- | -11.62 | -11.62 | 0.00 | 6.91 | 0.00 | -- | -- | 0.00 | -69.24 | -46.84 | -83.35 | -51.49 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.56 | -- | -21.54 | -- |
Cyclerion Therapeutics Inc | 0.00 | -10.47m | 7.18m | 1.00 | -- | 0.7591 | -- | -- | -4.26 | 1.27 | 0.00 | 3.49 | 0.00 | -- | -- | 0.00 | -103.82 | -72.70 | -150.23 | -86.96 | -- | -- | -- | -2,565.62 | -- | -- | 0.00 | -- | -100.00 | -- | 30.98 | -- | -- | -- |
Forte Biosciences Inc | 0.00 | -35.76m | 7.30m | 11.00 | -- | 0.4297 | -- | -- | -22.03 | -22.03 | 0.00 | 11.64 | 0.00 | -- | -- | 0.00 | -124.89 | -72.06 | -170.91 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
National Graphite Corp | 0.00 | -1.97m | 7.33m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
Kineta Inc | 0.00 | -20.88m | 7.49m | 11.00 | -- | -- | -- | -- | -1.79 | -1.79 | 0.00 | -0.6638 | 0.00 | -- | -- | 0.00 | -220.35 | -66.16 | -- | -86.61 | -- | -- | -- | -854.74 | -- | -- | -- | -- | 178.65 | 13.89 | 77.76 | -- | -- | -- |
Pulmatrix Inc | 11.39m | -10.84m | 7.56m | 22.00 | -- | 0.568 | -- | 0.6636 | -2.97 | -2.97 | 3.12 | 3.64 | 0.483 | -- | 21.64 | 517,818.20 | -45.97 | -46.91 | -52.76 | -58.12 | -- | -- | -95.18 | -238.04 | -- | -- | 0.00 | -- | 20.21 | 116.62 | 25.03 | -- | 104.29 | -- |
BioNexus Gene Lab Corp | 9.18m | -2.21m | 7.64m | 30.00 | -- | 0.7866 | -- | 0.8316 | -0.1108 | -0.1108 | 0.5807 | 0.5403 | 0.9647 | 7.19 | 5.77 | -- | -23.17 | -3.83 | -27.98 | -5.02 | 13.88 | 14.55 | -24.02 | -3.04 | 4.87 | -118.92 | 0.00 | -- | -10.60 | 115.07 | -638.56 | -- | 30.40 | -- |
Portage Biotech Inc | 0.00 | -71.08m | 7.73m | 7.00 | -- | 3.08 | -- | -- | -68.81 | -68.81 | 0.00 | 2.39 | 0.00 | -- | -- | 0.00 | -137.29 | -30.53 | -143.21 | -40.02 | -- | -- | -- | -- | -- | -- | 0.02 | -- | -- | -- | 27.98 | -- | -- | -- |
Mustang Bio Inc | 0.00 | -32.06m | 7.90m | 80.00 | -- | -- | -- | -- | -2.91 | -2.91 | 0.00 | -0.2384 | 0.00 | -- | -- | 0.00 | -170.53 | -70.02 | -727.24 | -79.98 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 33.44 | -- | -60.75 | -- |
Plus Therapeutics Inc (USA) | 5.51m | -13.23m | 7.96m | 20.00 | -- | -- | -- | 1.44 | -3.05 | -3.05 | 1.19 | -1.34 | 0.4336 | -- | -- | 275,450.00 | -104.14 | -59.18 | -- | -133.04 | -- | -- | -240.15 | -470.45 | -- | -4.17 | -- | -- | 2,093.30 | -5.89 | 34.32 | -- | 3.77 | -- |
Holder | Shares | % Held |
---|---|---|
Armistice Capital LLCas of 31 Mar 2024 | 1.05m | 8.54% |
PFG Investments LLCas of 30 Jun 2024 | 326.99k | 2.67% |
The Colony Group LLCas of 31 Mar 2024 | 92.40k | 0.75% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 59.33k | 0.48% |
Geode Capital Management LLCas of 30 Jun 2024 | 57.76k | 0.47% |
Renaissance Technologies LLCas of 30 Jun 2024 | 40.72k | 0.33% |
Citadel Securities LLCas of 31 Mar 2024 | 30.07k | 0.25% |
Millennium Management LLCas of 31 Mar 2024 | 29.24k | 0.24% |
Jane Street Capital LLCas of 31 Mar 2024 | 28.95k | 0.24% |
Two Sigma Securities LLCas of 31 Mar 2024 | 27.65k | 0.23% |